Home » Newsletters » BioWorld Science

BioWorld Science

April 6, 2011

View Archived Issues

MK-2206 advances to phase II testing in breast cancer

Phase II YF-476 trial begins recruitment of patients with Zollinger-Ellison syndrome

New PTEN/TP53/RB1 triple knockout model described of high-grade astrocytoma

Liver-selective glucokinase activator PFE-GKA-2 shows improved hypoglycemic control in vivo

RRx-001 to enter clinic as chemotherapeutic/radiosensitizer for cancer

Navitoclax enhances efficacy of taxanes in models of NSCLC

Vaccine based on rare adenoviral vectors is immunogenic in patients with HCV infection

Stealth Peptides presents phase I data on Bendavia

Probiodrug presents new glutaminyl cyclase inhibitors

Artemisinin is beneficial in patients with schizophrenia with elevated antibodies against T. gondii

Novel diacylglycerol O-acyltransferase 1 inhibitors reported

New androgen receptor ligands described by Bayer Schering Pharma

New compounds for treatment of HCV infection designed

FDA approves once-daily Viramune XR for use in combination for HIV-1 infection

United Paragon Associates patents new tachykinin NK2 receptor antagonists

OncoSec Medical and Inovio enter agreement for electroporation technology for cancer

Phase II PX-866 trial in glioblastoma begins enrollment

Quantum Genomics reports promising preclinical data on QGC-001

Merck & Co. acquires Inspire Pharma and expands ophthalmic pipeline

MedImmune enters strategic collaboration with Inserm Transfert

Progen Pharma completes enrollment in phase I trial of PG-11047

Favorable phase IIa data on NBI-98854 in patients with schizophrenia and tardive dyskinesia

Aragen Bioscience receives NIAID subcontracts to develop mAbs for infectious diseases

DARA BioSciences commences phase Ib study of DB-959

Enrollment completed in phase III trial of BEMA Buprenorphine for chronic pain

Celgene and ProMetic Life Sciences enter agreement for protein technologies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...